FDA’s Drug Review Challenge For 2013: Managing Sponsor Expectations

The first late-cycle meetings under FDA’s new drug review process are scheduled to start in February, and the agency is scrambling to manage expectations. What agency officials don’t want: a contentious fight over approvability, followed by a flood of new submissions and appeals. Industry’s response: Good luck with that.